PDA’s New Technical Report Highlights Data Integrity Management System for Pharma Labs
PDA Technical Report 80 (TR 80): Data Integrity in Laboratory Systems is the first in a series of three technical reports PDA will publish on data integrity.
The Parenteral Drug Association’s (PDA) new report, PDA Technical Report 80 (TR 80): Data Integrity in Laboratory Systems, is the first in a series of three technical reports that the association plans to publish on data integrity. TR 80 provides the framework and tools necessary to establish a data integrity management system for pharmaceutical laboratories.
Interpreting and meeting health authority expectations for data management and data integrity can be challenging, and laboratory systems can be especially complex due to the combination of manual, hybrid, and automated processing, PDA states. TR 80, which was developed by subject matter experts from the global pharmaceutical industry and regulatory agencies, discusses what is needed to establish a robust data integrity management system to ensure data integrity for paper, hybrid, and computerized systems within the laboratory.
The report is intended to outline regulatory requirements and expectations, along with best industry practices, to ensure data integrity, to highlight common gaps in laboratory data management practices, and to recommend methods of remediation.
Source: Parenteral Drug Association
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
